Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 6 Quarters

Analyst Consensus — 23 Analysts

17Buy

6Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$887Upside to Avg. PT-8.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Leerink Partners	David Risinger	PT Raise	Market Perform	$835→$997
Nov 2, 2026	Bernstein	Jeffrey Walch	PT Raise	Market Perform	$756→$812
Nov 2, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$779→$855
Nov 2, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$810→$913
Nov 2, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$780→$982
Nov 2, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$1030→$1100
Nov 2, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$750→$925
Nov 2, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$900→$1075
Nov 2, 2026	Canaccord Genuity	John Newman	PT Raise	Buy	$922→$1175
Nov 2, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$795→$980
Nov 2, 2026	Baird	Brian Skorney	PT Raise	Neutral	$761→$875
Nov 2, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$908→$1030
Oct 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$950→$1050
Oct 30, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$740→$825
Oct 28, 2026	Canaccord Genuity	John Newman	PT Raise	Buy	$875→$922
Oct 21, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$960→$980
Oct 19, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$854→$865
Oct 15, 2026	UBS	Trung Huynh	Upgrade	Neutral→Buy	$660→$978
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$737→$810
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$772→$780

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.

Benzinga Newsdesk

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

Bernstein analyst Jeffrey Walch maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $756 to $812.

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $779 to $855.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $810 to $913.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $780 to $982.

Benzinga Newsdesk

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

People Also Watch

People Also Watch

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PROBernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PROCNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PROMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRORBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PROTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982